Sanofi (SNY)
(Delayed Data from NSDQ)
$56.33 USD
+0.22 (0.39%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $56.32 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$56.33 USD
+0.22 (0.39%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $56.32 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum A VGM
Zacks News
Regeneron (REGN) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Investors' focus is likely to be on the performance of lead drugs Eylea and Dupixent when Regeneron (REGN) reports its second-quarter 2023 results.
Pharma Stock Roundup: AZN, SNY, ABBV Q2 Results, MRK, MRNA Cancer Jab in Phase III
by Kinjel Shah
AstraZeneca (AZN), Sanofi (SNY) and AbbVie (ABBV) announce second-quarter results.
Sanofi (SNY) Beats on Q2 Earnings, Misses Sales, Stock Down
by Zacks Equity Research
Sanofi (SNY) beats second-quarter estimates for earnings but misses the same for sales. It raises the projected earnings growth range for 2023.
Pharma Stock Roundup: JNJ, NVS Upbeat Q2 Results, FDA Nod to SNY & AZN RSV Antibody
by Kinjel Shah
FDA approves AstraZeneca (AZN) and Sanofi's (SNY) RSV antibody, Beyfortus. J&J (JNJ) and Novartis (NVS) announce strong second-quarter results.
Sanofi (SNY), AstraZeneca's RSV Antibody Gets FDA Nod in Infants
by Zacks Equity Research
Following FDA approval, Sanofi (SNY)/AstraZeneca's (AZN) Beyfortus is the first RSV antibody approved to protect all infants. The companies plan to make it available ahead of the upcoming RSV season.
Microsoft (MSFT) Agrees to Keep Call of Duty on Sony PlayStation
by Zacks Equity Research
Microsoft (MSFT) and Sony sign a deal to keep Call of Duty video game series on PlayStation consoles as its planned acquisition of Activision Blizzard appears closer to completion.
This is Why Sanofi (SNY) is a Great Dividend Stock
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes? Let's find out.
Is First Trust Value Line Dividend ETF (FVD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FVD
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Regeneron (REGN) Loses 13% in Three Months: What Lies Ahead?
by Zacks Equity Research
Regeneron (REGN) declines 13% in the last three months due to regulatory setback for 8 mg dose strength of aflibercept and competition for lead drug.
Sanofi (SNY) Atopic Dermatitis Drug Meets Goals in Phase II Study
by Zacks Equity Research
Sanofi's (SNY) phase II study, investigating amlitelimab for moderate-to-severe atopic dermatitis in adults, meets the primary endpoint.
Sanofi (SNY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Sanofi (SNY) closed at $53.67, marking a +0.36% move from the previous day.
Sanofi (SNY) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes? Let's find out.
Sanofi (SNY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Sanofi (SNY) closed at $50.72, marking a +0.4% move from the previous day.
FDA Panel Endorses AstraZeneca (AZN), Sanofi's RSV Antibody
by Zacks Equity Research
The FDA's AMDAC unanimously recommends AstraZeneca (AZN)/Sanofi's (SNY) nirsevimab as full immunization against RSV disease for all infants.
Innate (IPHA) Gains as Blood Cancer Drug Gets Fast Track Tag
by Zacks Equity Research
Innate (IPHA) and Sanofi's SAR'579 / IPH6101 get Fast Track Designation in the United States for the treatment of hematological malignancies.
Sanofi (SNY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Sanofi (SNY) closed at $51.54 in the latest trading session, marking a +1.3% move from the prior day.
GSK's RSV Vaccine Arexvy Gets EU Approval for Older Adults
by Zacks Equity Research
The approval of GSK's RSV vaccine for older adults is based on positive data from the pivotal AReSVi-006 phase III study.
Are You Looking for a High-Growth Dividend Stock?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes? Let's find out.
Sanofi (SNY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Sanofi (SNY) closed at $51.01 in the latest trading session, marking a +1.09% move from the prior day.
Pharma Stock Roundup: FDA Okays PFE RSV Jab for Elderly, AZN Ends Brazikumab Studies
by Kinjel Shah
FDA approves Pfizer's (PFE) RSV vaccine for older adults and AstraZeneca (AZN) and Merck's (MRK) Lynparza for BRCA-mutated metastatic castration-resistant prostate cancer
Pfizer's (PFE) RSV Vaccine for Older Adults Gets FDA Approval
by Zacks Equity Research
The FDA approves Pfizer's (PFE) RSV vaccine, Abrysvo, for older adults, making it the second RSV vaccine to be approved by the regulatory agency.
The Zacks Analyst Blog Highlights Fomento Economico Mexicano, NextEra Energy, Sanofi, NVIDIA and Enbridge
by Zacks Equity Research
Fomento Economico Mexicano, NextEra Energy, Sanofi, NVIDIA and Enbridge are included in this Analyst Blog.
Top Stock Reports for FEMSA, NextEra Energy & Sanofi
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Fomento Economico Mexicano, S.A.B. de C.V. (FMX), NextEra Energy, Inc. (NEE) and Sanofi (SNY).
Sanofi (SNY) NextGen Multiple Sclerosis Drug Meets Phase II Goal
by Zacks Equity Research
Sanofi's (SNY) phase II study on its novel investigational anti-CD40L antibody, frexalimab, meets the primary endpoint.